Moringa oleifera leaves alleviated inflammation through downregulation of IL-2, IL-6, and TNF-α in a colitis-associated colorectal cancer model

Researchers investigated whether Moringa oleifera leaves could reduce inflammation in a laboratory model of colitis-associated colorectal cancer. Colitis-associated colorectal cancer represents a serious complication where chronic inflammatory bowel disease progresses to cancer development. The study used an animal model to examine how moringa leaf treatment affected key inflammatory markers that drive this disease progression. The researchers measured three specific inflammatory proteins: interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), which are known to promote both inflammation and cancer development in the colon. Results showed that moringa leaf treatment successfully reduced levels of all three inflammatory markers, suggesting the plant's anti-inflammatory properties may help interrupt the pathway from chronic colitis to colorectal cancer. This finding matters because colitis-associated colorectal cancer affects patients with inflammatory bowel diseases like ulcerative colitis and Crohn's disease, who face significantly higher cancer risks than the general population. The study adds to growing evidence that moringa's bioactive compounds may help manage inflammatory conditions, though this research was conducted in laboratory animals rather than humans.